PDCD1 and metastatic melanoma: In patients with metastatic melanoma, objective response rates (ORR) ranging from 20% to 45% were observed after CTLA-4 or PD-1 (53), with response rates up to 60% observed when CTLA-4 was combined with PD-1 blockade (54, 55).